Alex N Eischeid, MD
Neurology · Des Moines
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Mercy Clinics Inc · 441 clinicians in this group
Looking this up.
Hospitals listed: Mercyone Des Moines Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Eischeid’s office at (515) 643-6290 to ask if they take your plan before you enroll.
California Medical Board record
Licence A161313 · Delinquent
Licence status: Delinquent · since 2019 · expires 2023-03-31 · University of Iowa Roy J. and Lucille A. Carver College of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mercyone Des Moines Medical CenterDes Moines, IAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 2 of 5 · 57% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.434, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.457, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.481, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 1,285 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Mercyone Des Moines Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.434 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.457 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.481 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 1,285 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0.12 to 1.79) · 2,108 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.74 to 1.18) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 213.67 (170.66 to 256.69) · 151 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3 · 378 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.6 · 436 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.2 · 634 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.5 · 533 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.7 · 654 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.9 · 5,747 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.36 (0.18 to 0.54) · 10,796 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.13 to 0.49) · 11,365 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (1.75 to 4.94) · 3,755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.15 (0.96 to 3.34) · 1,701 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.62 to 3.9) · 3,683 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.65 (6.05 to 13.25) · 1,741 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.58 (1.91 to 7.25) · 1,720 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.03 (0.64 to 3.42) · 601 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.4 (0 to 0.89) · 9,657 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 112 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 1.225 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.976 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.96 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.2 · 658 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.7 · 883 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.1 · 548 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 719 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -16.1 · 556 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 716 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 8.2) · 110 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.2 to 14) · 110 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.5 · 114 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 318 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 314 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.4 (8.9 to 14.5) · 2,140 cases | No different | Jan 2022 – Dec 2024 |
What patients said (674 patients answered, 21% of those asked)
| Cleanliness | 2 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 59% |
| Nurses "always" communicated well | 67% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 48% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 68% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 60% |
| Nurses "always" explained things so they could understand | 63% |
| Nurses "always" listened carefully | 64% |
| Nurses "always" treated them with courtesy and respect | 75% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 57% |
| Staff "always" explained possible side effects | 36% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$90,492
Medicare paid this office $90,492 for 397 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 186 | $24,323 | $94 |
| Return visit (30+ min) | 206 | $22,401 | $66 |
| New patient visit (60+ min) | 76 | $8,244 | $108 |
| New patient visit (45+ min) | 76 | $6,285 | $83 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 298 | $6,247 | $12 |
See all 13 services
| Long return visit (40+ min) | 186 | $24,323 | $94 |
| Return visit (30+ min) | 206 | $22,401 | $66 |
| New patient visit (60+ min) | 76 | $8,244 | $108 |
| New patient visit (45+ min) | 76 | $6,285 | $83 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 298 | $6,247 | $12 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 20 | $5,054 | $99 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 19 | $3,488 | $67 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 23 | $2,508 | $34 |
| Return visit (30+ min) | 15 | $1,905 | $91 |
| Long return visit (40+ min) | 14 | $1,891 | $100 |
| Short return visit (20+ min) | 19 | $1,208 | $46 |
| Muscle electrical test | 28 | $979 | $13 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 21 | $413 | $12 |
Who their Medicare patients are
397 Original Medicare patients in 2024. Average age 74 · Under 65 5% · 85 and older 9% · Women 48% · Also on Medicaid 6% · Health risk score 1.27. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 68% · Depression 33% · Diabetes 28% · Coronary heart disease 25% · Chronic kidney disease 21% · Cancer 16% · Atrial fibrillation 15% · Heart failure 12% · Dementia 12% · Stroke 10% · COPD 8%.
The office billed $259,312, Medicare allowed $126,300 and paid $90,492; for 2,249 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 397 | 2,249 | 74 | 1.27 | $259,312 | $90,492 |
| 2023 | 389 | 864 | 74 | 1.36 | $179,900 | $71,212 |
| 2022 | 304 | 481 | 74 | 1.39 | $126,641 | $52,365 |
| 2021 | 327 | 827 | 74 | 1.59 | $318,148 | $75,194 |
| 2020 | 162 | 235 | 73 | 1.43 | $89,172 | $23,283 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Long return visit (40+ min) | 131 | $18,599 | $99 |
| Return visit (30+ min) | 113 | $11,422 | $72 |
| New patient visit (60+ min) | 66 | $8,334 | $126 |
| New patient visit (45+ min) | 77 | $7,367 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $6,080 | $129 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,249 | $99 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 11 | $2,951 | $102 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 17 | $1,922 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $1,868 | $60 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 17 | $1,557 | $36 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,360 | $91 |
| Short return visit (20+ min) | 19 | $1,104 | $50 |
| Muscle electrical test | 17 | $536 | $14 |
2022: 6 services
| New patient visit (60+ min) | 117 | $15,191 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $13,933 | $150 |
| Long return visit (40+ min) | 81 | $12,694 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $2,480 | $77 |
| New patient visit (45+ min) | 20 | $1,753 | $88 |
| Return visit (30+ min) | 14 | $1,197 | $75 |
2021: 8 services
| Long return visit (40+ min) | 248 | $45,977 | $114 |
| New patient visit (60+ min) | 53 | $8,492 | $160 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 17 | $4,392 | $125 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 115 | $4,162 | $28 |
| Return visit (30+ min) | 27 | $2,246 | $83 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 11 | $2,137 | $89 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 13 | $1,015 | $39 |
| Muscle electrical test | 23 | $871 | $18 |
2020: 4 services
| Long return visit (40+ min) | 66 | $7,641 | $103 |
| New patient visit (60+ min) | 41 | $6,375 | $155 |
| New patient visit (45+ min) | 22 | $2,615 | $119 |
| Return visit (30+ min) | 24 | $1,751 | $70 |
Medicaid work
$4,504 in 2024
Medicaid paid $4,504 for 73 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Hospital outpatient clinic visit for assessment and management of a patient | 73 | $4,504 |
| 2024 | 73 | 1 | 14 | $4,504 |
| 2023 | 50 | 1 | 15 | $2,380 |
| 2022 | 25 | 2 | 13 | $2,000 |
| 2021 | 14 | 1 | 14 | $947 |
See the largest Medicaid services in earlier years
2023
| Hospital outpatient clinic visit for assessment and management of a patient | 50 | $2,380 |
2022
| Hospital outpatient clinic visit for assessment and management of a patient | 12 | $1,021 |
| New patient visit (60+ min) | 13 | $979 |
2021
| Long return visit (40+ min) | 14 | $947 |
Drugs they prescribed that Part D paid
$245,972
Pharmacies billed $245,972 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,843) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
1,729 generic and 114 brand-name prescriptions · $245,972 in drug cost · 23 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 31 | $48,651 | $1,569 |
| Neupro | None | 40 | $47,797 | $1,195 |
| Carbidopa-Levodopa | None | 970 | $28,052 | $29 |
| Gocovri | None | 12 | $19,624 | $1,635 |
| Propranolol Hcl Er | None | 132 | $5,244 | $40 |
See all 25 drugs
| Rytary | Parkinson's | 31 | $48,651 | $1,569 |
| Neupro | None | 40 | $47,797 | $1,195 |
| Carbidopa-Levodopa | None | 970 | $28,052 | $29 |
| Gocovri | None | 12 | $19,624 | $1,635 |
| Propranolol Hcl Er | None | 132 | $5,244 | $40 |
| Primidone | None | 103 | $3,888 | $38 |
| Carbidopa-Levodopa-Entacapone | None | 11 | $2,425 | $220 |
| Carbidopa-Levodopa Er | None | 63 | $2,255 | $36 |
| Amantadine | None | 44 | $2,173 | $49 |
| Ropinirole Er | None | 11 | $1,415 | $129 |
| Propranolol | None | 41 | $1,109 | $27 |
| Ropinirole | None | 14 | $744 | $53 |
| Midodrine | None | 13 | $646 | $50 |
| Rivastigmine | None | 20 | $604 | $30 |
| Donepezil | None | 69 | $586 | $8 |
| Quetiapine | None | 18 | $482 | $27 |
| Memantine | None | 24 | $363 | $15 |
| Mirtazapine | None | 16 | $340 | $21 |
| Gabapentin | None | 36 | $335 | $9 |
| Clonazepam | None | 23 | $313 | $14 |
| Levetiracetam | None | 15 | $196 | $13 |
| Topiramate | None | 11 | $130 | $12 |
| Escitalopram | None | 15 | $120 | $8 |
| Trazodone | None | 14 | $39 | $3 |
| Sertraline | None | 15 | $34 | $2 |
Year by year
| 2024 | 1,843 | 343 | 0% (0) | 6% | $245,972 |
| 2023 | 1,027 | 204 | 0% (0) | 8% | $186,300 |
| 2022 | 650 | 178 | 0% (0) | 12% | $178,536 |
| 2021 | 983 | 177 | 0% (0) | 11% | $442,840 |
| 2020 | 293 | 122 | 0% (0) | 8% | $73,924 |
| 2019 | 142 | 48 | 0% (0) | 11% | $59,157 |
| 2018 | 105 | 36 | 0% (0) | 12% | $47,753 |
| 2017 | 143 | 39 | 0% (0) | 16% | $41,937 |
| 2016 | 151 | 41 | None | 26% | $10,549 |
| 2015 | 32 | None | 0% (0) | None | $3,982 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Neupro | None | 20 | $28,261 | $1,413 |
| Carbidopa-Levodopa | None | 473 | $24,817 | $52 |
| Gocovri | None | 14 | $23,787 | $1,699 |
| Rytary | Parkinson's | 14 | $20,113 | $1,437 |
| Ubrelvy | None | 15 | $16,037 | $1,069 |
| Aimovig | Migraine | 11 | $8,598 | $782 |
| Propranolol Hcl Er | None | 78 | $4,632 | $59 |
| Propranolol | None | 44 | $3,525 | $80 |
| Primidone | None | 69 | $3,460 | $50 |
| Amantadine | None | 26 | $2,248 | $86 |
| Carbidopa-Levodopa Er | None | 31 | $2,045 | $66 |
| Donepezil | None | 68 | $877 | $13 |
| Gabapentin | None | 25 | $373 | $15 |
| Topiramate | None | 13 | $288 | $22 |
2022: 12 drugs
| Nuplazid | Parkinson's psychosis | 13 | $77,958 | $5,997 |
| Rytary | Parkinson's | 20 | $26,737 | $1,337 |
| Neupro | None | 21 | $21,863 | $1,041 |
| Carbidopa-Levodopa | None | 274 | $9,768 | $36 |
| Amantadine | None | 49 | $3,857 | $79 |
| Propranolol Hcl Er | None | 31 | $2,745 | $89 |
| Carbidopa-Levodopa Er | None | 46 | $2,407 | $52 |
| Primidone | None | 34 | $1,654 | $49 |
| Propranolol | None | 15 | $353 | $24 |
| Donepezil | None | 27 | $304 | $11 |
| Gabapentin | None | 16 | $244 | $15 |
| Clonidine | None | 12 | $41 | $3 |
2021: 15 drugs
| Nuplazid | Parkinson's psychosis | 38 | $192,266 | $5,060 |
| Rytary | Parkinson's | 34 | $42,488 | $1,250 |
| Carbidopa-Levodopa | None | 331 | $26,599 | $80 |
| Neupro | None | 15 | $19,271 | $1,285 |
| Amantadine | None | 102 | $8,750 | $86 |
| Carbidopa-Levodopa Er | None | 124 | $6,538 | $53 |
| Propranolol Hcl Er | None | 32 | $2,063 | $64 |
| Rivastigmine | None | 18 | $1,830 | $102 |
| Primidone | None | 30 | $1,040 | $35 |
| Propranolol | None | 27 | $957 | $35 |
| Gabapentin | None | 26 | $730 | $28 |
| Escitalopram | None | 20 | $414 | $21 |
| Donepezil | None | 21 | $337 | $16 |
| Clonazepam | None | 45 | $246 | $5 |
| Pramipexole Dihydrochloride | None | 11 | $208 | $19 |
2020: 5 drugs
| Rasagiline Mesylate | 11 | $10,080 | $916 |
| Carbidopa-Levodopa | 88 | $4,520 | $51 |
| Carbidopa-Levodopa Er | 25 | $2,841 | $114 |
| Amantadine | 31 | $2,407 | $78 |
| Gabapentin | 15 | $162 | $11 |
2019: 3 drugs
| Carbidopa-Levodopa Er | 11 | $1,112 | $101 |
| Carbidopa-Levodopa | 29 | $835 | $29 |
| Levetiracetam | 20 | $500 | $25 |
2018: 4 drugs
| Tetrabenazine | 12 | $39,738 | $3,311 |
| Atorvastatin | 18 | $596 | $33 |
| Levetiracetam | 14 | $343 | $25 |
| Gabapentin | 17 | $124 | $7 |
2017: 3 drugs
| Atorvastatin | 29 | $561 | $19 |
| Levetiracetam | 12 | $251 | $21 |
| Clopidogrel | 11 | $114 | $10 |
2016: 4 drugs
| Ranexa | 11 | $3,504 | $319 |
| Zetia | 11 | $3,026 | $275 |
| Levetiracetam | 15 | $463 | $31 |
| Metoprolol | 11 | $72 | $7 |
2015: 1 drug
| Levetiracetam | 15 | $484 | $32 |
Money from drug and device companies
$124 in 2025
| 2025 | 2 | 3 | None | $124 |
| 2024 | 1 | 1 | None | $28 |
| 2023 | 1 | 2 | None | $62 |
| 2022 | 2 | 9 | None | $1,265 |
| 2019 | 1 | 1 | None | $13 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Vyalev | $109 | 2 payments
|
| Ge Healthcare | None | $16 | 1 payment
|
See all 3 published payments
| Abbvie | Meals · 2025-11-10 | Vyalev | $84 |
| Ge Healthcare | Meals · 2025-06-04 | None | $16 |
| Abbvie | Meals · 2025-04-08 | Botox | $25 |
See earlier years (2024, 2023, 2022, 2019)
2024: $28
| Ge Healthcare | None | $28 | 1 payment
|
2023: $62
| Abbvie | Ubrelvy | $62 | 2 payments
|
2022: $1,265
| Medtronic | Percept PC Brainsense | $1,187 | 8 payments
|
| Janssen Pharmaceuticals | Ponvory | $78 | 1 payment
|
2019: $13
| Boston Scientific | General Dbs | $13 | 1 payment
|
Professional record
- NPI
- 1689055790
- Licence
- CA A161313, IA MD-49047, IA R-10297California A161313: Delinquent · expires 2023-03-31
- Group
- Mercy Clinics Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- Po Box 1475, Des Moines, IA, 50305
- NPI first listed
- 2015-06-15
- NPI last updated
- 2022-01-17
- NPI record certified
- 2022-01-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 200 Hawkins Dr, Iowa City, IA, 52242 · 300 Pasteur Dr, Stanford, CA, 94305